Welcome to our dedicated page for ANGIODYNAMICS SEC filings (Ticker: ANGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ANGIODYNAMICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ANGIODYNAMICS's regulatory disclosures and financial reporting.
DONNELLY HOWARD W reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc director Howard W. Donnelly received a grant of 11,887 shares of common stock on July 15, 2026, representing 11,887 restricted stock units granted as regular annual compensation for board service. These units vested immediately, increasing his directly held common stock to 178,938 shares.
Burgess Lorinda reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics director Lorinda Burgess received an equity award of 11,887 restricted stock units as regular annual compensation for board service on July 15, 2026. These RSUs immediately vested at grant, increasing her directly held common stock to 67,144 shares. The award was a no-cost stock grant and was not made under a Rule 10b5-1 trading plan.
AngioDynamics Inc director Auen Eileen O'Shea reported the acquisition of 11,887 shares of common stock, representing 11,887 restricted stock units granted as regular annual compensation for board service. These units vested immediately at grant, bringing her direct holdings to 116,605 shares of AngioDynamics common stock.
Tarnoff Michael E reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics director Michael E. Tarnoff received a grant of 11,887 shares of common stock on July 15, 2026, representing restricted stock units granted as regular annual director compensation that immediately vested at grant. After this award, he directly holds 95,265 common shares, and the transaction was not made under a Rule 10b5-1 trading plan.
Trowbridge Stephen A reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics EVP and CFO Stephen A. Trowbridge received equity awards on July 15, 2026. He was granted 53,257 restricted stock units, vesting in four equal annual installments each July 15 from 2027 through 2030, and 53,257 performance rights, each a contingent right to one share of common stock. Payout on the performance rights can range from 0% up to 240% of the target, based on relative total shareholder return over a three-year performance period. After the restricted stock unit award, his directly held common stock reported in this line totals 297,819 shares.
Piccinini Laura reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. senior vice president of international operations Laura Piccinini received equity awards on July 15, 2026. She was granted 19,860 restricted stock units, each representing a contingent right to one common share, vesting in four equal annual installments from July 15, 2027 through July 15, 2030, bringing her direct common stock holdings to 78,388 shares. She also received 19,860 performance rights, each tied to one share of common stock, with between 0% and 200% of the target amount earned over a three-year period and a potential 20% adjustment, for a maximum payout of up to 240% of the target based on total shareholder return relative to a peer group.
Nighan Warren JR reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. reported that SVP Quality and Regulatory Warren Nighan Jr. received equity awards on July 15, 2026. He was granted 17,966 restricted stock units, vesting in four equal annual installments from July 15, 2027 through 2030, and 17,966 performance rights tied to three-year relative total shareholder return. Following the RSU grant, he directly holds 84,092 shares of common stock.
AngioDynamics Inc. reported that officer Chad Thomas Campbell, SVP/GM Vascular Access, received equity awards on July 15, 2026. He acquired 16,081 restricted stock units, each convertible into one share of common stock, vesting in four equal annual installments on July 15 of 2027, 2028, 2029 and 2030. He also received 16,081 performance rights, each representing a contingent right to one share, with 0–200% of the target (plus a possible 20% adjustment, for up to 240% of target) earned based on three-year total shareholder return relative to a peer group. Following these grants, he directly held 104,540 shares of common stock.
Weiss Lawrence T reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics SVP and Chief Legal Officer Lawrence T. Weiss received equity-based compensation on July 15, 2026. He was granted 21,288 restricted stock units, each representing a contingent right to one share of common stock, plus 21,288 performance rights, also initially tied one-for-one to common shares.
The restricted stock units vest in four equal annual installments on July 15 of 2027, 2028, 2029 and 2030. The performance rights are earned over a three-year performance period based on total shareholder return versus a peer group, with a potential payout from 0% up to 240% of the 21,288-share target; any unearned awards are forfeited. Following these grants, Weiss directly holds 112,618 shares of common stock.
AngioDynamics Inc. executive Lawrence T. Weiss, SVP and Chief Legal Officer, reported an exempt disposition of 2,267 shares of common stock on July 16, 2026. The shares were withheld at $14.14 per share to satisfy tax obligations from vesting restricted stock units granted July 16, 2025, leaving 91,330 shares held directly.